Cited by 119Pancreatic function and diabetesTissue Engineering and Regenerative MedicineElectrospun Nanofibers in Biomedical Applications

A nanofibrous encapsulation device for safe delivery of insulin-producing cells to treat type 1 diabetes

Open access
Wang, Xi, Maxwell, Kristina G., Wang, Kai, Bowers, Daniel T., Flanders, James A., Liu, Wanjun, Wang, Long-Hai, Liu, Qingsheng +9 more·2021·Science Translational Medicine

Abstract

A nanofibrous cell encapsulation device containing rodent/human islets or human stem cell–derived β cells treats diabetes in rodents.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.abb4601

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mice transplant outcomes for SC-islets within a microencapsulation device were more favorable in the intraperitoneal cavity than in the subcutaneous space due to a much lower fibrotic response.

    “Similarly, mice transplant outcomes for SC-islets within a microencapsulation device were more favorable in the intraperitoneal cavity than in the subcutaneous space due to a much lower fibrotic response.102”

    From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [102]

    The Results section on NICE-device biocompatibility (page not provided) reports much less fibrotic overgrowth on blank devices in the intraperitoneal space than in subcutaneous sites in mice. The SC-β-cell transplantation results do not compare graft outcomes between those sites, so the claimed difference in SC-islet outcomes—and its attribution to fibrosis—is not established. The paper describes a tubular nanofibrous device, not a microencapsulation device. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [44]Pepper AR, Gala-Lopez B, Pawlick R, Merani S, Kin T, Shapiro AMJ, A prevascularized subcutaneous device-less site for islet and cellular transplantation, Nat Biotechnol 33, 518– 523 (2015). 25893782
  2. [55]Omer A, Duvivier-Kali VF, Trivedi N, Wilmot K, Bonner-Weir S, Weir GC, Survival and maturation of microencapsulated porcine neonatal pancreatic cell clusters transplanted into immunocompetent diabetic mice, Diabetes 52, 69– 75 (2003). 12502495

Cited by

Sorted by citations

Authors
Wang, X., Maxwell, K. G., Wang, K., Bowers, D. T., Flanders, J. A., Liu, W., Wang, L.-H., Liu, Q., Liu, C., Naji, A., Wang, Y., Wang, B., Chen, J., Ernst, A. U., Melero-Martin, J. M., Millman, J. R., & Ma, M.
Affiliations
  • Cornell University (US)
  • Washington University in St. Louis (US)
  • Boston Children's Hospital (US)
  • Hospital of the University of Pennsylvania (US)
  • University of Virginia (US)
  • Department of Cardiac Surgery, Boston Children’s Hospital, Boston, MA 02115, USA.
Corresponding author
  • Millman, Jeffrey R.
  • Ma, Minglin
Venue
Science Translational Medicine
Published
2021-06-02
Volume
13
Issue
596
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W3164081747
Cited by
119
References
74
Citations by year
2026: 10 · 2025: 14 · 2024: 33 · 2023: 25 · 2022: 25 · 2021: 12
FWCI
22.29
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (1R01DK105967-01A1, 5R01DK114233, T32DK108742)
  • National Institute of Diabetes and Digestive and Kidney Diseases (10028044)
  • Hartwell Foundation
  • JDRF (5-CDA-2017-391-A-N, 2-SRA-2018-472-S-B)
  • Novo Nordisk Company
Topics
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
  • Physical Sciences › Materials Science › Biomaterials › Electrospun Nanofibers in Biomedical Applications
Keywords
type 1 diabetes, stem cell-derived beta cells, cell encapsulation, nanofibrous scaffolds, electrospinning, islet transplantation, xenotransplantation, peritoneal implantation, xenogeneic immune response, diabetes reversal
MeSH terms
Animals, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 1, Dogs, Insulin, Islets of Langerhans Transplantation, Insulin-Secreting Cells, Mice, Nanofibers, Insulins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review